About Our Guidelines
The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines are a collection of consensus statements developed by experts to help oncologists determine when and how to best use immunotherapy to treat their patients. The guidelines are created using a systematic process to ensure the recommendations are unbiased, relevant, and facilitate clinical decision-making.
These disease-specific Cancer Immunotherapy Guidelines offer a vital resource for the practicing oncology community. SITC uses as a model the 2011 National Academy of Medicine's (formerly Institute of Medicine) 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to assure a fair, transparent and balanced process for creating each consensus statement. Each Cancer Immunotherapy Guideline subcommittee comprises a comprehensive mix of academic physicians and researchers, nurses, patients, and patient advocates invited from institutions across the United States, and are reviewed on a quarterly basis with reference to newly available clinical trial data and FDA approvals.
Each expert committee addresses knowledge gaps in our understanding of immunotherapy treatments for their disease specialty, and develops evidence-based recommendations by evaluating the published literature and providing their opinions on key issues, documenting alternative opinions when they occur.